The Antibody Production Core (APC) is designed to improve the efficiency of the three Program Project laboratories in all phases of monoclonal antibody production and purification. The APC Director will assist investigators in the appropriate immunization of animals, collection of immune sera and provide information on possible antibody screening strategies to Project Scientists. Cell fusion and the subsequent cloning and cryopreservation of specific hybridomas will be performed by the Washington University School of Medicine Hybridoma Center. Once the desired hybridomas have been identified by the Project Scientists, the Antibody Production Core will generate antibody-containing supernatants, purify these monoclonal antibodies and provide to the Program Project Laboratories purified quantities of monoclonal antibody derived from ten liter cultures of hybridoma cells.
| Matsui, Ken; O'Mara, Leigh A; Allen, Paul M (2003) Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol 15:797-805 |
| Krug, Anne; Uppaluri, Ravindra; Facchetti, Fabio et al. (2002) IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol 169:6079-83 |
| Dunn, Gavin P; Bruce, Allen T; Ikeda, Hiroaki et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-8 |
| Ikeda, Hiroaki; Old, Lloyd J; Schreiber, Robert D (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109 |
| Hanson, H L; Donermeyer, D L; Ikeda, H et al. (2000) Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265-76 |
